These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Reducing immunoreactivity of porcine bioprosthetic heart valves by genetically-deleting three major glycan antigens, GGTA1/β4GalNT2/CMAH. Zhang R; Wang Y; Chen L; Wang R; Li C; Li X; Fang B; Ren X; Ruan M; Liu J; Xiong Q; Zhang L; Jin Y; Zhang M; Liu X; Li L; Chen Q; Pan D; Li R; Cooper DKC; Yang H; Dai Y Acta Biomater; 2018 May; 72():196-205. PubMed ID: 29631050 [TBL] [Abstract][Full Text] [Related]
12. Human antibody recognition of xenogeneic antigens (NeuGc and Gal) on porcine heart valves: could genetically modified pig heart valves reduce structural valve deterioration? Lee W; Long C; Ramsoondar J; Ayares D; Cooper DK; Manji RA; Hara H Xenotransplantation; 2016 Sep; 23(5):370-80. PubMed ID: 27511593 [TBL] [Abstract][Full Text] [Related]
13. Influence of fixation conditions on the performance of glutaraldehyde-treated porcine aortic valves: towards a more scientific basis. Broom ND; Thomson FJ Thorax; 1979 Apr; 34(2):166-76. PubMed ID: 113899 [TBL] [Abstract][Full Text] [Related]
14. Viscoelasticity of dynamically fixed bioprosthetic valves. II. Effect of glutaraldehyde concentration. Duncan AC; Boughner D; Vesely I J Thorac Cardiovasc Surg; 1997 Feb; 113(2):302-10. PubMed ID: 9040624 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the cross-linking characteristics of porcine heart valves fixed with glutaraldehyde or epoxy compounds. Sung HW; Shen SH; Tu R; Lin D; Hata C; Noishiki Y; Tomizawa Y; Quijano RC ASAIO J; 1993; 39(3):M532-6. PubMed ID: 8268592 [TBL] [Abstract][Full Text] [Related]